Research programme: haematological malignancies therapeutics - Janssen Biotech/Novera Therapeutics/OICR/UHN

Drug Profile

Research programme: haematological malignancies therapeutics - Janssen Biotech/Novera Therapeutics/OICR/UHN

Latest Information Update: 17 Oct 2015

Price : $50

At a glance

  • Originator Novera Therapeutics; Ontario Institute for Cancer Research; University Health Network
  • Developer Janssen Biotech; Novera Therapeutics; Ontario Institute for Cancer Research; University Health Network
  • Class Small molecules
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Research Haematological malignancies

Most Recent Events

  • 14 Oct 2015 Janssen Biotech enters into a research collaboration and option and license agreement with Novero Therapeutics, Ontario Institute for Cancer Research and University Health Network to co-develop therapeutics for Haematological malignancies
  • 14 Oct 2015 Early research in Haematological malignancies in Canada (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top